Evidence map›Paper›PMID 31053121›Full record

ArticleBMC pulmonary medicine2019

Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry.

Helen E Jo, Tamera J Corte, Ian Glaspole, Christopher Grainge, Peter M A Hopkins, Yuben Moodley, Paul N Reynolds, Sally Chapman, E Haydn Walters, Christopher Zappala and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Cough in Idiopathic Pulmonary Fibrosis.Frontiers in rehabilitation sciences · 2021
    Review
  18. Phenotypes of Gastroesophageal Reflux Disease: Where Rome, Lyon, and Montreal Meet.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2020
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 1 country.

Helen E JoDepartment of Respiratory Medicine, Royal Prince Alfred Hospital, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia. helen.jo@sydney.edu.au.ORCID http://orcid.org/0000-0003-1183-2729
Tamera J CorteDepartment of Respiratory Medicine, Royal Prince Alfred Hospital, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.
Ian GlaspoleNational Health and Medical Research Council Centre of Research Excellence in Pulmonary Fibrosis, University of Sydney, Sydney, NSW, Australia.
Christopher GraingeNational Health and Medical Research Council Centre of Research Excellence in Pulmonary Fibrosis, University of Sydney, Sydney, NSW, Australia.
Peter M A HopkinsNational Health and Medical Research Council Centre of Research Excellence in Pulmonary Fibrosis, University of Sydney, Sydney, NSW, Australia.
Yuben MoodleyNational Health and Medical Research Council Centre of Research Excellence in Pulmonary Fibrosis, University of Sydney, Sydney, NSW, Australia.
Paul N ReynoldsDepartment of Respiratory Medicine, Royal Adelaide Hospital, Adelaide, SA, Australia.
Sally ChapmanDepartment of Respiratory Medicine, Royal Adelaide Hospital, Adelaide, SA, Australia.
E Haydn WaltersNational Health and Medical Research Council Centre of Research Excellence in Pulmonary Fibrosis, University of Sydney, Sydney, NSW, Australia.
Christopher ZappalaDepartment of Thoracic Medicine, Royal Brisbane & Women's Hospital, Brisbane, QLD, Australia.
Heather AllanLung Foundation Australia, Brisbane, QLD, Australia.
Gregory J KeirDepartment of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Wendy A CooperFaculty of Medicine, University of Sydney, Sydney, NSW, Australia.
Annabelle M MaharTissue pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Samantha EllisDepartment of Radiology, The Alfred Hospital, Melbourne, VIC, Australia.
Sacha MacanshLung Foundation Australia, Brisbane, QLD, Australia.
Nicole S GohNational Health and Medical Research Council Centre of Research Excellence in Pulmonary Fibrosis, University of Sydney, Sydney, NSW, Australia.
The University of Sydney · AULung Foundation Australia · AURoyal Adelaide Hospital · AUPrincess Alexandra Hospital · AURoyal Brisbane and Women's Hospital · AURoyal Prince Alfred Hospital · AUThe Alfred Hospital · AU

Funding

National Health and Medical Research Council APP1066128
6 · The paper itself

Abstract

BACKGROUND AND

objectiveGastroesophageal reflux disease (GORD) is highly prevalent in idiopathic pulmonary fibrosis (IPF) and may play a role in its pathogenesis. Recent IPF treatment guidelines suggest that all patients with IPF be considered for antacid therapy. However, emerging evidence suggests that antacid therapy does not improve IPF patient outcomes and may increase the risk of pulmonary infection.

methodsUsing prospectively collected data from the Australian IPF Registry including use of antacid therapy, GORD diagnosis and GORD symptoms, the relationship of these GORD variables to survival and disease progression was assessed. The severity of GORD symptoms using the frequency scale for symptoms of GORD (FSSG) and its relationships to outcomes was also assessed for the first time in an IPF cohort.

resultsFive hundred eighty-seven (86%) of the 684 patients in the Australian IPF Registry were eligible for inclusion. Patients were mostly male (69%), aged 71.0 ± 8.5 years with moderate disease (FVC 81.7 ± 21.5%; DLco 48.5 ± 16.4%). Most patients were taking antacids (n = 384; 65%), though fewer had a diagnosis of GORD (n = 243, 41.4%) and typical GORD symptoms were even less common (n = 171, 29.1%). The mean FSSG score was 8.39 ± 7.45 with 43% (n = 251) having a score > 8. Overall, there was no difference in survival or disease progression, regardless of antacid treatment, GORD diagnosis or GORD symptoms.

conclusionsNeither the use of antacid therapy nor the presence of GORD symptoms affects longer term outcomes in IPF patients. This contributes to the increasing evidence that antacid therapy may not be beneficial in IPF patients and that GORD directed therapy should be considered on an individual basis to treat the symptoms of reflux.

Indexed as

AgedAntacidsAustraliaDisease ProgressionFemaleGastroesophageal RefluxHumansIdiopathic Pulmonary FibrosisKaplan-Meier EstimateLungMaleMiddle AgedProspective StudiesRegistriesSeverity of Illness IndexTreatment OutcomeAntacidsAntacidCoughGastroesophageal reflux diseaseIdiopathic pulmonary fibrosisRegistry

Identifiers

PMID31053121
PMCPMC6499965
OpenAlexW2947958698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.